Miracle and/or Minefield? GLP-1 RA Drugs and Eating Disorders

Abstract Purpose of Review Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the treatment of obesity and type 2 diabetes (T2D), but their rapid uptake has outpaced understanding of their effects in individuals with eating disorders (EDs). GLP-1 RAs produce sustained effects on appetite, satiety, food reward, and energy intake, raising the possibility of markedly different consequences across ED presentations. Recent Findings Preliminary studies suggest potential benefit for binge-eating symptoms, consistent with emerging evidence of overlap between binge eating and reward- and impulse-related pathways. Conversely, appetite suppression and attenuation of compensatory responses to negative energy balance could facilitate or mask restriction in individuals vulnerable to anorexia nervosa (AN) or atypical anorexia nervosa (AAN). Empirical evidence remains sparse. Summary We review neurobiological and genetic evidence relevant to these potentially divergent effects, summarize the clinical literature, and highlight implications for screening and monitoring. Determining who may benefit, who may be harmed, and how to identify risk before treatment should be priorities for future research.

Authors

Institutions

Publication Details

Journal
Current Psychiatry Reports
Published
2026-11-17
DOI
https://doi.org/10.1007/s11920-026-01726-9
Primary Topic
Eating Disorders and Behaviors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Miracle and/or Minefield? GLP-1 RA Drugs and Eating Disorders

Rachel Presskreischer, Cynthia Marie Bulik, Laura Marie Thornton, Amanda Banks et al.
Current Psychiatry Reports
Eating Disorders and Behaviors
article

Miracle and/or Minefield? GLP-1 RA Drugs and Eating Disorders

Rachel Presskreischer, Cynthia Marie Bulik, Laura Marie Thornton, Amanda Banks, Anna Meehan
article en

Abstract

Abstract Purpose of Review Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the treatment of obesity and type 2 diabetes (T2D), but their rapid uptake has outpaced understanding of their effects in individuals with eating disorders (EDs). GLP-1 RAs produce sustained effects on appetite, satiety, food reward, and energy intake, raising the possibility of markedly different consequences across ED presentations. Recent Findings Preliminary studies suggest potential benefit for binge-eating symptoms, consistent with emerging evidence of overlap between binge eating and reward- and impulse-related pathways. Conversely, appetite suppression and attenuation of compensatory responses to negative energy balance could facilitate or mask restriction in individuals vulnerable to anorexia nervosa (AN) or atypical anorexia nervosa (AAN). Empirical evidence remains sparse. Summary We review neurobiological and genetic evidence relevant to these potentially divergent effects, summarize the clinical literature, and highlight implications for screening and monitoring. Determining who may benefit, who may be harmed, and how to identify risk before treatment should be priorities for future research.

Current Psychiatry ReportsVol. 28(1)
University of North Carolina at Chapel Hill (US), Philadelphia VA Medical Center (US)
Eating Disorders and Behaviors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon